Amsterdam Molecular Therapeutics Launches Equity Offering of up to EUR 15 Million

Not for release, publication or distribution in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to US persons. This announcement is not a prospectus and is not an offer for sale of securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.

AMSTERDAM, October 5, 2010 - Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT)
announces today the launch of an equity offering by means of a private
placement to certain institutional investors, other qualifying investors who
subscribe for at least EUR 50,000 per investor in various jurisdictions, and
the members of the Board of Management with the aim to raise net proceeds of
EUR 15 million (the "Private Placement").

AMT's key shareholders Advent Venture Partners, Gilde Healthcare
Partners, Credit Agricole Private Equity and Forbion Capital Partners, have
committed to subscribe for new shares in the Private Placement for an
aggregate amount of EUR 3.75 million. The members of the Board of Management
have expressed their intention to participate in the Private Placement.

Kempen & Co and Petercam Nederland are acting as joint global
coordinators and bookrunners for the Private Placement, which shall be
structured as an accelerated bookbuilding process. The accelerated
bookbuilding process shall start with immediate effect and is expected to
close on Thursday 7 October, subject to acceleration or extension of the
timetable of the Private Placement and barring unforeseen circumstances.

The issue price and number of shares to be issued pursuant to the Private
Placement will be determined on the outcome of the accelerated bookbuilding
process and will be announced in a subsequent press release. Payment and
settlement of the new shares and their admission to trading and listing on
NYSE Euronext in Amsterdam is expected to occur on October 12, 2010.

The net proceeds of the Private Placement will increase AMT's financial
flexibility and will be used to fund Glybera(R) through its regulatory and
commercial development and to continue the development of the hemophilia and
other pipeline programs.

The prospectus, which has been prepared in relation to the admission to
listing and trading of the new shares, has been made generally available
through the AMT website, and will be available through the website of NYSE
Euronext.

There will be no offering of the new shares in the United States. The new
shares will be offered outside the United States in "offshore transactions"
within the meaning of, and pursuant to Regulation S. under the U.S.
Securities Act of 1933, as amended.

About Amsterdam Molecular Therapeutics

AMT is a leader in the development of human gene based therapies. Using
adeno-associated viral (AAV) derived vectors as the delivery vehicle of
choice for therapeutic genes, the company has been able to design and
validate what is probably the first stable and scalable AAV production
platform. This proprietary platform can be applied to a large number of rare
(orphan) diseases that are caused by one faulty gene. Currently, AMT has a
product pipeline with several AAV-based gene therapy products in LPLD,
Hemophilia B, Duchenne Muscular Dystrophy, Acute Intermittent Porphyria, and
Parkinson's Disease at different stages of research or development. AMT was
founded in 1998 and is based in Amsterdam.

Not for release, publication or distribution in whole or in part,
directly or indirectly, in or into the United States, Australia, Canada,
Japan or South Africa or to US persons. This announcement is not a prospectus
and is not an offer for sale of securities in the United States, Canada,
South Africa, Australia, Japan or any other jurisdiction.

The securities mentioned herein have not been and will not be registered
under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and
may not be offered or sold in the United States absent registration under the
Securities Act or an available exemption from, or in a transaction not
subject to, the registration requirements of the Securities Act.

In connection with the admission of the shares in the capital of
Amsterdam Molecular Therapeutics (AMT) Holding N.V. to listing and trading on
NYSE Euronext in Amsterdam a prospectus has been made generally available
(the "Prospectus"). The Prospectus is available at no cost through the
website of AMT, and will also be available via the website of NYSE Euronext
(Dutch residents only) and by sending a request in writing to AMT (P.O. Box
22506, 1100 DA Amsterdam, The Netherlands).

————————————————————————-

Certain statements in this press release are "forward-looking statements"
including those that refer to management's plans and expectations for future
operations, prospects and financial condition. Words such as "strategy,"
"expects," "plans," "anticipates," "believes," "will," "continues,"
"estimates," "intends," "projects," "goals," "targets" and other words of
similar meaning are intended to identify such forward-looking statements.
Such statements are based on the current expectations of the management of
AMT only. Undue reliance should not be placed on these statements because, by
their nature, they are subject to known and unknown risks and can be affected
by factors that are beyond the control of AMT. Actual results could differ
materially from current expectations due to a number of factors and
uncertainties affecting AMT's business.

AMT expressly disclaims any intent or obligation to update any
forward-looking statements herein except as required by law. For a more
detailed description of the risk factors and uncertainties affecting AMT,
reference is made to the Prospectus and AMT's public announcements made from
time to time.

PRN NLD

For further enquiries: Ellen Roest, AMT Communications, Mobile +31-6-2900-6179, e.roest at amtbiopharma.com, Jorn Aldag, CEO, Tel +31-20-566-7394, j.aldag at amtbiopharma.com; Media: Mike Sinclair, Halsin Partners, Mobile +44-20-7318-2955, msinclair at halsin.com; Investors: Oscar Izeboud, Kempen & Co, Tel +31(0)20-348-8480, Oscar.izebout at kempen.nl; Raymond de Wolff, Petercam Nederland, Tel. +31(0)20-573-5504, Raymond.dewolff at petercam.nl